The graded version: a real mechanism worth an open question, a wrong peptide family in the viral version, and — stated plainly — zero human data in either direction.
“Peptides cause cancer” is now a sentence millions of people have heard — most recently from AsapSCIENCE’s June 2026 video on BPC-157, which reached a mainstream audience of millions. Sellers answer it with a shrug. Both responses skip the actual record. Here is that record, graded the way we grade everything: what is mechanism-plausible, what is claimed in the other direction, and what is simply unknown.
What is mechanism-plausible
Blood-vessel growth (angiogenesis). BPC-157’s best independently replicated mechanism is pro-angiogenic: Hsieh and colleagues at Chang Gung University, Taiwan (Journal of Molecular Medicine, 2017) — a group with no connection to the compound’s Zagreb originators — showed BPC-157 upregulates the VEGFR2 receptor and activates the VEGFR2–Akt–eNOS pathway in blood-vessel cells, with vessel growth in animal and chick models; a 2020 Scientific Reports study mapped a second arm of the same pathway. This matters because VEGFR2 is the principal receptor targeted by anti-angiogenic cancer drugs (the bevacizumab class), and roughly half of human cancers depend on VEGF/VEGFR2 signaling to build their blood supply. Independent reviewers (Józwiak et al., 2025) have raised exactly this as an open safety question: a mechanism that grows blood vessels is, in principle, a plausible tumor-promoting pathway. That is a legitimate, literature-raised concern. It is also, so far, a mechanism in search of an outcome — see “what is unknown,” below.
The growth-hormone axis (a class caution, not a compound finding). Peptides that raise growth hormone (the secretagogue class) sit downstream of a well-established association: chronic growth-hormone and IGF-1 excess, as in acromegaly, carries elevated risk for several cancers. Regulators treat the whole axis with care for that reason. As a caution about a class of compounds it is fair. It is not evidence about any single peptide.
What is claimed in the other direction
Thin — thinner than promoters suggest:
- The only direct anti-tumor experiment is Radeljak, Seiwerth & Sikirić (2004) — a conference abstract, from the Zagreb group itself, reporting that BPC-157 inhibited melanoma-cell growth in a dish. It has never been replicated in more than twenty years, and there is no published in-vivo study showing tumor-growth or metastasis inhibition. (Zagreb’s 2025 journal comment rebutting the tumor hypothesis cites reduced melanoma lung metastases in mice; the underlying record remains the group’s own.)
- Kang et al. (2018), in mice bearing colon adenocarcinoma, found BPC-157 counteracted cancer cachexia (wasting) and prolonged survival — but did not reduce tumor volume.
An unreplicated 2004 abstract from the inventor’s lab, pointing one way, and an unreplicated 2017 mechanism from an independent lab, pointing the other. That is the whole direct literature.
What is simply unknown — stated plainly
- Zero human data. No clinical trial has ever evaluated tumor growth, promotion, or metastasis for BPC-157 — or ruled any of it out.
- Zero attributed cancers. No documented human cancer has been attributed to BPC-157 in any source we can find.
- Zero carcinogenicity studies. The standard long-term animal carcinogenicity work that would normally exist for a drug candidate has never been published for this compound.
McGuire and colleagues (“Regeneration or Risk?”, 2025) land where the evidence lands: the tumor question is entirely untested in humans. Anyone who tells you BPC-157 causes cancer is ahead of the record. Anyone who tells you it has been shown not to is equally ahead of it. The honest sentence is: the studies that would answer this question have never been run.
Sidebar: the trefoil mix-up — a correction the viral video needs
The AsapSCIENCE video builds much of its cancer segment on trefoil factor peptides, saying they “contribute to the movement of cancer cells… part of the metastasis process… detected in numerous tumors,” and presents BPC-157 in their frame. Two corrections:
- BPC-157 is not a trefoil peptide. The trefoil factor family (TFF1, TFF2, TFF3) is defined by the trefoil (P) domain — a compact three-disulfide-bond fold that resists digestion in the gut. BPC-157 is a linear 15-amino-acid fragment of a different gastric protein (the “body protection compound”). It contains no trefoil domain and is not a member of the family. Evidence about trefoil peptides does not describe BPC-157.
- Even the trefoil story is two-directional. TFF3 genuinely is implicated in tumor progression — overexpressed in breast, colorectal, prostate, gastric and liver cancers, and shown to promote cell migration, invasion and blood-vessel signaling. But in the largest recent breast-cancer analysis (2026, combining TCGA data with tissue validation), high TFF3 expression was an independent protective factor for overall survival. Context, subtype and cancer type flip the sign. The family is not a one-way “cancer peptide” story even on its own terms.
Why this matters beyond one video: the trefoil bridge is how a real-but-theoretical mechanism acquired the emotional weight of established metastasis evidence. Separating the families is the correction. Our full fact-check of the video grades every claim, including the ones the video got right — which are substantial.
The bottom line
- Mechanism-plausible concern: yes (angiogenesis via VEGFR2; GH-axis class caution).
- Evidence that BPC-157 causes cancer in humans: none.
- Evidence that it does not: also none.
- Studies that could settle it: never run.
That combination — a plausible mechanism and an empty evidence file — is precisely why this site routes medical questions to licensed clinicians rather than to comment sections, ours included. See the doctors directory and our Legal Mandate.
Educational information only — not medical or legal advice. Status as of November 9, 2026. Sources: Hsieh et al., J Mol Med 2017; Józwiak et al., Pharmaceuticals 2025; Radeljak et al., Melanoma Research 2004 (abstract); Kang et al., Curr Pharm Des 2018; McGuire et al., Curr Rev Musculoskelet Med 2025. See Our Legal Mandate.